MedPlus Health

BHold

MEDPLUS · NSE · Small Cap · Pharmacy Retail

Pharmacy Retail

Fetching live…

₹800

1D -0.3%1M -1.5%1Y -12%

Fundamental (RQ-100)

Technical (TQ-100)

Valuation

Market cap

₹9.5K Cr

Live decision ratingCSell / Avoid

Fundamental score breakdown

48/100

Growth Quality

15.4 / 20

Rev 1Y 18.0%, 3Y CAGR 22.0%, 5Y CAGR 20.0%

Margin & Profitability

1.5 / 15

EBITDA 5.0%, PAT 1.5%

Return on Capital

4.4 / 20

ROCE 8.0%, ROE 4.0%

Cash Flow Quality

4.0 / 15

OCF/EBITDA 0.55

Leverage

8.0 / 10

ND/EBITDA 0.80

Reinvestment

7.0 / 8

Capex/Sales 4.0%

Accounting

4.0 / 7

Governance

4.0 / 5

Technical score breakdown

40/100

Trend Structure

8.0 / 20

↓ 200 · ↓ 50 · ↓ 20

Momentum

5.0 / 15

1Y -12.0%, 1M -1.5%

Volume Dynamics

8.0 / 15

Vol30 —%

Relative Strength

4.0 / 15

1Y -12.0%

MA Cluster

5.0 / 10

Extension

5.0 / 10

—% from 50DMA

Volatility

4.0 / 8

Price Action

1.0 / 7

-100.0% from 52W H

Business

What this company actually does

Omnichannel pharmacy chain. South India anchored.

Stores

4,500

Dark stores

—

Cities

800

Listed status

Listed

Format exposure

How direct is this play?

Primary formatPharmacy Retail

Exposure typePure-play

Revenue visibilityMedium

Operating leverage stageInvestment

Policy beneficiaryNone

Data confidenceMedium

Financial snapshot

Live · green dot = live, falls back to curated

Revenue

₹6.5K Cr

Rev 1Y growth

18%

Rev 3Y CAGR

22%

EBITDA margin

5.0%

PAT margin

1.5%

ROE

ROCE

OCF/EBITDA

0.55

Net Debt/EBITDA

0.8

Financial statements

Multi-year P&L, balance sheet, cash flow — scraped live from Screener.in

Fetching from Screener.in…

Loading…

Valuation

Live multiples + retail-specific (curated)

P/E

110

Forward P/E

EV/EBITDA

EV/Sales

1.4

P/B

5.0

FCF Yield

2.1%

Mid-range valuation. Watch incremental ROCE.

Investment thesis

AI-generated · always cite sources before acting

Bull

Compounding revenue at 22% CAGR. Pure-play exposure to Pharmacy Retail. Long-runway TAM with structural tailwinds.

Base

Earnings growth of ~24% over the next 3 years assuming margins hold. Multiple compression risk if growth slows; multiple expansion possible if Pharmacy Retail GMV outperforms.

Bear

Capital efficiency below cost of capital. Format-level risk: regulation, gig-cess, or competitive pressure compress contribution margin.

Variant perception

Consensus views MedPlus Health as a challenged player. Our differentiated take: the current multiple already prices in mid-cycle outcomes.

Key monitorables

Quarterly EBITDA margin trajectory
Revenue growth vs management guidance
Capex vs store/dark-store adds
Promoter holding and ESOP dilution

Peers

Same primary format · sorted by market cap